INTRODUCTION
Hospital-acquired pneumonia (HAP) is one of the most dreaded infections, accounting for five to at least 20 cases per 1000 hospital admissions [1 && ,2,3]. Approximately 40% of HAP infections are acquired in the ICU, and of these, 90% are ventilator-associated pneumonia (VAP) [3, 4] . VAP is defined as pneumonia that develops at least 48 h after endotracheal intubation. Regardless of the nomenclature used, HAP/VAP is commonly associated with negative impact on patient outcomes, and huge hospital resources are spent to treat these infections [4] .
Nearly 30% of HAP/VAP may be caused by multidrug-resistant (MDR) pathogens [5] , and these infections carry a significant risk of mortality, with mortality rates approaching 80% [6, 7] . Potential MDR pathogens, such as Acinetobacter baumannii and Pseudomonas aeruginosa, are becoming increasingly difficult to treat as they are commonly less susceptible to common antibiotics [8 & ,9 & ]. The alarming increase of these pathogens, coupled with the diminishing antibiotic pipeline, has forced clinicians to vigorously search for potential strategies that can optimize the use of the antibiotics available at present.
As sub-optimal antibiotic therapy has been linked with poor outcomes in HAP/VAP [10 & ,11], appropriate antibiotic administration is an essential intervention in this patient cohort. However,
APPLIED CLINICAL PHARMACOLOGY OF ANTIBIOTICS
Pharmacology deals with two main principles: pharmacokinetics and pharmacodynamics. Pharmacokinetics describes the processes from absorption to elimination of drugs. For an antibiotic, pharmacodynamics describes the relationship between pharmacokinetic exposure (i.e. drug concentration) and its pharmacological effect (i.e. ability to kill or inhibit the growth of a pathogen). Essentially, this relationship can be explained by linking the concentration of an antibiotic with the corresponding minimum inhibitory concentration (MIC) of the offending pathogen. On the basis of the pharmacokinetic/pharmacodynamic principles, antibiotics can be classified into three categories that represent their modes of bacterial killing [9 & ,16] , and these fundamental concepts of antibiotic kill characteristics are further illustrated in Fig. 1 . Applying these concepts to guide antibiotic treatment will ensure that the prescribed antibiotic dose is optimized for the causative pathogens.
KEY POINTS
Antibiotic administration is challenging in critically ill patients with HAP/VAP as conventional dosing guidelines rarely consider the altered physiology and illness severity associated with this patient population.
Physicochemical characteristics of an antibiotic should be considered when dosing patients with HAP/ VAP infections.
The application of an aggressive pharmacokinetic/ pharmacodynamic target is justified in critically ill patients with HAP/VAP as antibiotic dosing that achieves the pharmacokinetic/pharmacodynamic target in plasma is unlikely to achieve the same target in ELF.
Alternative dosing strategies, which exploit the pharmacokinetic/pharmacodynamic properties of an antibiotic, should be strongly considered to ensure optimal antibiotic exposure and better therapeutic outcomes in patients with MDR HAP/VAP infections. FIGURE 1. Fundamental concepts of antibiotic kill characteristics based on pharmacokinetic/pharmacodynamic parameters. For concentration-dependent antibiotics, the ratio of maximal drug concentration (C max ) to minimum inhibitory concentration (C max / MIC) predicts bacterial killing, and hence, increasing concentrations result in progressively increased killing. Conversely, timedependent antibiotic killing activity is strongly correlated with the duration of time that drug concentration remains above the MIC during a dosing interval ( fT >MIC ) and as such, maintaining the duration of effective drug exposure leads to greater efficacy. However, some antibiotics are found to display both properties where the ratio of area under the concentration-time curve over a dosing interval (AUC) to MIC (AUC/MIC) describes bacterial killing and higher thresholds are associated with optimal outcomes.
FACTORS AFFECTING ANTIBIOTIC EXPOSURE IN PATIENTS WITH PNEUMONIA
Optimal antibiotic concentration is needed in the interstitial fluid of tissues as most antibiotic-bacteria interactions are thought to occur here. Importantly, most antibiotics are unevenly distributed, and plasma concentration does not always reflect concentrations at the infected tissues [14, 17, 18] . For pneumonia, causative pathogens are commonly concentrated in lung compartments and cells such as epithelial lining fluid (ELF) and alveolar macrophages [18] . It follows that any method of administration that could increase antibiotic penetration into these tissues will enhance the likelihood for therapeutic success. However, the extent of ELF and alveolar macrophage penetration can be influenced by two main factors: drug's physicochemical properties; and patient-specific characteristics.
Antibiotic penetration and drug's physicochemical characteristics
Lipophilic antibiotics have excellent penetration into the alveolar compartments [14, 18] . The ELFto-plasma concentration ratio (C ELF : C Plasma ) of these antibiotics is commonly reported to be at least 1. Conversely, hydrophilic antibiotics have poorer and variable ELF penetration [19] [20] [21] [22] [23] . The C ELF : C Plasma of beta-lactam antibiotics and aminoglycosides may vary between 0.3-0.8 [19] [20] [21] [22] [23] [24] Table 1 summarizes some of the relevant data on antibiotic penetration into ELF. Essentially, these data indicate the importance of considering the physicochemical characteristics of a drug when dosing antibiotics for patients with pneumonia. As optimal antibiotic dosing is commonly adjudicated based on plasma drug concentrations, as opposed to those at the ELF or alveolar macrophages, aggressive dosing regimens may be required to ensure effective pharmacokinetic/pharmacodynamic target attainment in infected lung tissues [17] .
Pathophysiological changes in patients with pneumonia that can affect drug pharmacokinetics
Nearly half of all HAPs are reported in critically ill patients, and 30-60% of these are associated with MDR pathogens [5, 15] . This sub-group of patients may likely demonstrate severe pathophysiological derangements that can alter antibiotic pharmacokinetics [13] ; the most important alterations are those concerning the primary pharmacokinetic parameters, namely volume of distribution (V d ) and clearance, which primarily influence dosing requirements. Changes in antibiotic V d and clearance have been increasingly reported in critically ill patients [29] , and the relevance of the two phenomena in determining optimal antibiotic exposure has been reviewed in detail elsewhere [13] . . Given the inherent risk for MDR pathogen involvement, one of the current recommendations is to provide empirical coverage for the problematic pathogens. The antibiotics that are commonly used in empirical treatment of MDR HAP/VAP are discussed in this section. Optimal dosing strategies, which exploit the pharmacokinetic/pharmacodynamic characteristics of each antibiotic, will also be suggested to enhance the likelihood of therapeutic success in patients with MDR HAP/VAP.
OPTIMAL ANTIBIOTIC DOSING IN

Beta-lactam antibiotics
The beta-lactam antibiotics include penicillins, cephalosporins, monobactams and carbapenems. These antibiotics demonstrate variable ELF penetration [19] [20] [21] [22] [23] [24] 30 
The fT >MIC is regarded as the optimal pharmacodynamic index which best predicts their killing activity [16] . Specifically, the % fT >MIC required for bactericidal effect is 60-70%, 50% and 40% for cephalosporins, penicillins and carbapenems, respectively [16] . However, recent clinical data suggest potential benefits from higher and longer antibiotic exposures than those described in preclinical studies [36, 37] . It has been advocated that beta-lactam concentrations should be maintained as at least four to five times MIC for extended periods during each dosing interval, particularly in patients with severe infections [38 & ]. The application of an aggressive pharmacokinetic/pharmacodynamic target is also justified in patients with HAP/VAP infections, because antibiotic dosing that achieves pharmacokinetic/pharmacodynamic target in plasma is unlikely to achieve the same target in ELF.
Continuous infusion and extended infusion, which can also be referred to as prolonged infusion, 
Fluoroquinolones
Fluoroquinolones are mostly lipophilic and these antibiotics demonstrate excellent penetration into the alveolar compartments [55] [56] [57] [58] . Specifically, the C ELF : C Plasma of these antibiotics is commonly reported to be at least 1 when administered by either the oral or intravenous (i.v.) route. This antibiotic class displays largely concentration-dependent kill characteristics with some time-dependent features [16] . It has been suggested that the area under the concentration-time curve over a 24-h period (AUC 0-24 )/MIC best predicts its bactericidal effect, even better than the C max /MIC ratio, and a ratio of at least 125 and at least 30 is required for optimal patient outcomes in the treatment of Gram-negative and Gram-positive infections, respectively [59] . However, standard doses of fluoroquinolones rarely achieve these pharmacokinetic/pharmacodynamic targets, particularly in the treatment of pathogens with high MICs [59, 60] . Furthermore, their clinical usage has been currently restricted due to rapid emergence of bacterial resistance and without local microbiology data to guide treatment; fluoroquinolone monotherapy should be avoided in the management of VAP [61] . When this antibiotic class is used in combination, dosing should seek to maximize C max /MIC as this ensures optimal AUC 0-24 / MIC ratio and by citing ciprofloxacin as an example, the goal may be achieved with a 400-mg 8-hourly or 600-mg 12-hourly regimen. The higher dosing regimens have also been observed to achieve the required AUC 0-24 /MIC ratio in the ELF of patients with severe pneumonia [58] .
Aminoglycosides
Although previous studies have suggested that achieving a C max /MIC ratio of 10-12 predicts optimal outcome against Gram-negative pathogens [62] , several investigators have since suggested that an AUC 0-24 /MIC ratio of 80-160 better predicts aminoglycoside efficacy [63] . The pharmacokinetics of aminoglycosides is profoundly altered in severe infections, leading to sub-optimal plasma drug exposure [64, 65, 66 && , 67, 68] . This was recently illustrated by Roger et al. [66 && ] in a prospective study of 90 ICU patients receiving either amikacin or gentamicin for various types of severe infections. In this cohort, 81% failed to achieve the targeted C max with standard dosing. As these antibiotics poorly penetrate the pulmonary compartments [25, 26, 69] , it could then be inferred that standard aminoglycosides doses would rarely achieve the requisite pharmacokinetic/pharmacodynamic target in the alveolar compartments of patients with HAP/VAP. Accordingly, the usage of higher aminoglycoside doses (e.g. amikacin 30 mg/kg or gentamicin 8 mg/kg) combined with extended-daily dosing is being increasingly employed for this antibiotic class [64, 66 && ]. Similar to fluoroquinolones, monotherapy of this class is discouraged in the management of VAP, but nevertheless, it remains the commonly used antibiotic as part of empiric double anti-pseudomonal coverage in critically ill patients.
Colistin
Colistin demonstrates concentration-dependent kill characteristics with a significant in-vitro post-antibiotic effect against Gram-negative pathogens [9 & ]. An AUC 0-24 /MIC ratio of 50-65 has been suggested as the optimal pharmacokinetic/pharmacodynamic index, although higher indices were also described in thigh infection models [70] . Although colistin has been evaluated in several clinical studies [71] [72] [73] , there are currently very limited data to guide optimal dosing for patients with HAP/VAP [74] . Furthermore, conflicting and variable reports of colistin ELF concentrations have been published [75] [76] [77] ; most of these reports, however, highlighted the need for higher colistin doses to treat critically ill patients with severe pneumonia. A dosing regimen which includes an i.v. loading dose of 9 MU of colistin methanesulfonate followed by 4.5 MU twice-daily has now been validated in a critical care setting in the treatment of MDR infections [73] . However, colistin monotherapy is currently not advocated, particularly in patients with moderate-to-good renal function and for pathogens with MICs of at least 1 [78, 79] . Furthermore, its use is often restricted by neurotoxicty and nephrotoxicity.
Vancomycin
Although vancomycin demonstrates time-dependent kill characteristics [80] , the ratio of C max /MIC has also been found to be equally important for its bactericidal effect [81] . It has been generally accepted that achieving a high ratio of AUC 0-24 / MIC best predicts clinical success. Specifically, a ratio of AUC 0-24 /MIC at least 400 is needed for an optimal bacteriological and clinical outcome in the treatment of S. aureus respiratory infections [82, 83] , whereas higher exposures, such as AUC 0-24 /MIC ratio of at least 578, are needed when treating critically ill patients with septic shock [84] . However, standard vancomycin dosing rarely achieves these pharmacokinetic/pharmacodynamic targets in the ELF of patients with pneumonia due to poor lung penetration [27, 28] . Due to the common practice of measuring trough concentrations when vancomycin is used, a trough concentration of at least 15-20 mg/L should be maintained in the plasma of patients with HAP/VAP to enhance drug concentrations in the alveolar compartments [85] . To achieve the aim, a loading dose of 25-30 mg/kg followed by 40 mg/kg/day should be considered [86 & ,87,88] . However, it is also important to highlight that it is challenging to attain the optimal pharmacokinetic/pharmacodynamic target for vancomycin when the methicillin-resistant S. aureus (MRSA) isolates have MICs of at least 1 mg/L [89] . Owing to this phenomenon and its poor lung penetration [14] , empirical use of vancomycin for MRSA pneumonia may be considered unreliable, and this has since led to the increasing interest in the potential role of linezolid.
Linezolid
Linezolid belongs to an antibiotic class known as the oxazolidinones, which was developed for the treatment of Gram-positive infections. Rayner et al. [90] reported that optimal linezolid activity correlates well with the ratio of AUC 0-24 /MIC, with a ratio of 80-120 predicting the likelihood of therapeutic success in patients with pneumonia. Some in-vivo animal studies also described linezolid as a timedependent antibiotic where an fT >MIC of 40% is required for optimal bactericidal effect [91, 92] . A standard dose of 600 mg 12-hourly commonly achieves these optimal pharmacokinetic/pharmacodynamic targets in the ELF as linezolid demonstrates excellent C ELF : C Plasma ratio [93, 94] . Therefore, the usage of linezolid, in preference to high-dose vancomycin, has been increasingly advocated for the treatment of MRSA pneumonia. However, previous meta-analyses did not demonstrate clinical superiority favouring linezolid over vancomycin in terms of bacteriological eradication, clinical cure and patient survival [95] [96] [97] . Although a recent RCT reported that the use of linezolid was associated with a higher rate of clinical success when compared to vancomycin, the 60-day mortality rates were similar in both groups [98] . Nevertheless, linezolid should be preferred when risk factors of acute kidney injury are evident and the MIC of vancomycin is at least 1 mg/l.
Nebulized antibiotics
The usage of nebulized antibiotics is currently appealing because the method of drug administration can achieve an airway-drug concentration of 100-300-fold higher than the MIC of most bacteria, including the MDR pathogens [99] . In a double-blind RCT recruiting 42 ICU patients who were infected with MDR pathogens, nebulized antibiotics successfully eradicated the pathogens without any signs of systemic toxicity and development of antibiotic resistance [100] . In a meta-analysis of 812 patients comparing outcomes of nebulized antibiotics (AEi.v. antibiotics) versus i.v. antibiotics alone, Zampieri et al. [101 && ] reported higher clinical cure rates favouring the nebulized antibiotics treatment arm, although no difference in patient survival was observed. Although largely promising, the most effective dosing regimen for most nebulized antibiotics remains unclear. Furthermore, nebulized antibiotic therapy requires specific ventilator settings that cannot be applied to all patients [102] .
Several antibiotics have been studied as inhaled agents; aminoglycosides [99, 100] , ceftazidime [103] , colistin [74] and imipenem/cilastatin have been evaluated in several studies as part of combination therapies of nebulized antibiotics and i.v. antibiotics in the treatment of MDR VAP. Importantly, the overall results were encouraging and generally suggest potential benefits with this route of administration. However, more high-quality evidence is still needed to evaluate the effects of nebulized antibiotics on patient outcomes.
CONCLUSION
Profound pathophysiological changes in critically ill patients with HAP/VAP may significantly reduce effective antibiotic exposure. As conventional antibiotic dosing does not adequately address these alterations, alternative dosing strategies may be required to ensure optimal therapeutic outcomes.
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